All In MedTech

Device Trial Radar · NCT03127722

Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

An Open-label, Non-randomized, Prospective Observational Cohort Study to Assess Post-procedural Outcomes in Two Cohorts of Women Who Chose to Undergo Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

990

Actual

Start

May 3, 2017

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
BayerNot on our public-company list
Sponsor type
Industry
First posted
Apr 25, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
Female only, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess post-procedural outcomes for women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization, including: * Pelvic and/or lower abdominal pain * Abnormal uterine bleeding * Surgical intervention (including "insert removal" and hysterectomy) * Allergic, hypersensitivity, or autoimmune-like reactions

Conditions

  • Contraception

Interventions

  • Blood drawProcedure

    Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

  • ESSURE (BAY1454032)Device

    Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

  • Laparoscopic tubal sterilizationProcedure

    Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal SterilizationTime frame: Up to 60 months
  2. Bleeding: The Proportion of Subjects Reporting AEs of Abnormal Uterine Bleeding (AUB) After Insertion of Essure System Compared to the Proportion of Subjects Reporting AEs of AUB After Laparoscopic Tubal SterilizationTime frame: Up to 60 months
  3. Proportion of Subjects With Reported Allergic/Hypersensitivity ReactionsTime frame: Up to 60 months

2 more outcomes with a free account

Locations

57 sites in 1 country. Site status is shown where the registry gives one.

  • New Horizons Women's Care

    Chandler, Arizona

  • Precision Trials, AZ, LLC

    Phoenix, Arizona

  • Visions Clinical Research - Tucson

    Tucson, Arizona

54 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.